Abstract Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer
disease (AD) biomarker will require identification of brain regions that are most important in …

In several neurodegenerative diseases that are collectively called tauopathies, progressive
accumulation of tau in the brain is closely associated with neurodegeneration and cognitive …

Advances in our understanding of the mechanisms of tau-mediated neurodegeneration in
Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent …

PET neuroimaging of amyloid-β (Aβ) provides an in vivo biomarker for pathologic changes
associated with Alzheimer disease (AD). Aβ-targeted agents have been approved by the …

The detection and staging of Alzheimer's disease (AD) using non-invasive imaging
biomarkers is of substantial clinical importance. Positron emission tomography (PET) …

Accepted: 14 October 2014/Published online: 31 October 2014© Springer-Verlag Berlin
Heidelberg 2014 and only at the same predilection sites as the tau lesions that are present …

Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …

Alzheimer's disease (AD) is defined by amyloid (A) and tau (T) pathologies, with T better
correlated to neurodegeneration (N). However, T and N have complex regional relationships …

To accurately predict the development of Alzheimer's disease (AD) at its predementia stage
would be a major breakthrough from both therapeutic and research standpoints. In this …

In addition to the deposition of β-amyloid plaques, neurofibrillary tangles composed of
aggregated hyperphosphorylated tau are one of the pathological hallmarks of Alzheimer's …